The telomerase reverse transcriptase (TERT) gene promoter mutation was found to be in 80.3% of primary GBM and 28.6% of secondary GBM and found to predict overall poor survival in patients who had incomplete resections and no temozolomide chemotherapy [34]. The gene discussed is TERT; the disease is glioblastoma.